Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?

被引:10
|
作者
Kuang, Ze-Min [1 ]
机构
[1] Capital Med Univ, Dept Hypertens, Beijing Anzhen Hosp, Beijing 100029, Peoples R China
关键词
CARDIOVASCULAR RISK-FACTORS; SYSTOLIC BLOOD-PRESSURE; SERUM-CHOLESTEROL; STATIN USE; ALZHEIMERS-DISEASE; DEMENTIA; DECLINE; ASSOCIATION; MIDLIFE; HYPERTENSION;
D O I
10.1155/2020/1484357
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk factors for cardiovascular disease such as hypertension and hyperlipidemia are associated with cognitive decline. However, there is still no clear evidence that the use of antihypertensive or lipid-lowering therapy can prevent or delay cognitive decline or development of dementia. To provide a reference for clinical treatment, we analyzed the potential mechanisms of cognitive dysfunction induced by hypertension and hyperlipidemia, the clinical research and controversy of antihypertensive and lipid-lowering therapies on cognitive function, and the clinical value of combined antihypertensive and lipid-lowering therapy. It is currently believed that hypertension and elevated blood cholesterol levels in middle-aged people may be related to cognitive impairment or dementia in the elderly. Some studies suggest that intensive antihypertensive or lipid-lowering therapies are better than standard antihypertensive or lipid-lowering therapy, yet further tests are needed to confirm their effects on cognitive function. Actively controlling potential risk factors from middle age may be important for Alzheimer's disease (AD) prevention.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Pharmacogenomics of lipid-lowering therapies
    Hu, Miao
    Tomlinson, Brian
    PHARMACOGENOMICS, 2013, 14 (08) : 981 - 995
  • [12] Complementary lipid-lowering therapies
    McDermott, JH
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (16) : 1668 - 1671
  • [13] Lipid-lowering Therapies in Myositis
    Mizus, Marisa C.
    Tiniakou, Eleni
    CURRENT RHEUMATOLOGY REPORTS, 2020, 22 (10)
  • [14] Combined lipid-lowering therapy: choosing strategy and tactics
    Koziolova, N. A.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2010, 9 (04): : 107 - 115
  • [15] Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients
    Egede, Rasmus
    Jensen, Lisette Okkels
    Hansen, Henrik Steen
    Antonsen, Lisbeth
    Hansen, Knud Norregaard
    Junker, Anders
    Thayssen, Per
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 158 (03) : 376 - 379
  • [16] The dawn of a new era of targeted lipid-lowering therapies
    Tokgozoglu, Late
    Libby, Peter
    EUROPEAN HEART JOURNAL, 2022, 43 (34) : 3198 - +
  • [17] Bempedoic acid: A new player in lipid-lowering therapies
    Cuevas, Ada
    Alonso, Rodrigo
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 615 - 616
  • [18] The antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Flack, JM
    Nasser, SA
    CURRENT HYPERTENSION REPORTS, 2003, 5 (03) : 189 - 191
  • [19] Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010
    Tuppin, Philippe
    Ricci-Renaud, Pauline
    de Peretti, Christine
    Fagot-Campagna, Anne
    Gastaldi-Menager, Christelle
    Danchin, Nicolas
    Alla, Francois
    Allemand, Hubert
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (05) : 274 - 286
  • [20] Exploring New Combination Strategy of Lipid-Lowering Therapies for Primary Prevention of Cardiovascular Disease
    Cho, Jun Hwan
    Cho, Eun Jeong
    Jeong, Young-Hoon
    KOREAN CIRCULATION JOURNAL, 2024, 54 (09) : 545 - 548